Vertex Pharmaceuticals (VRTX) Lifts Revenue Guidance, Is It Still A Bargain?

Vertex Pharmaceuticals (VRTX) gave investors fresh information to work with after its latest quarterly report and an updated full year outlook that raised total revenue guidance for 2026.

Recent trading reflects that story. The share price is up 7.26% over the past month and 21.00% year to date, while the 1-year total shareholder return of 33.61% and 5-year total shareholder return of 192.11% suggest momentum that has been building rather than fading.

Scan for other healthcare leaders with similar momentum by checking our hand picked 35 healthcare AI stocks, which are also using advanced science and data to reshape patient outcomes.

For Vertex Pharmaceuticals, the recent jump could signal that investors are reacting to fresh guidance and product traction rather than a mood swing in sentiment. The valuation question now is how much of that story is already reflected in the price.

Most Popular Narrative: 24% Undervalued

Against a last close of $547.09, the most followed fair value estimate of $723.43 implies plenty of future progress is already being debated in Vertex Pharmaceuticals, with the current price sitting well below what optimistic models imply.

The kidney disease franchise is broadening beyond IgA nephropathy as inaxaplin’s Phase IIb AMPLIFIED data open up modest proteinuria and type 2 diabetes cohorts and the Phase III AMPLITUDE trial targets accelerated approval on a 1 year eGFR endpoint. At the same time, povetacicept runs through multiple renal and neurologic indications. Successful readouts could turn what is often modelled as a single product line into a multi indication business that adds several billion dollars of largely specialty margin revenue on top of the cystic fibrosis base.

See why 3 investors see Vertex Pharmaceuticals as 24% undervalued.

Result: Fair Value of $723.43 (UNDERVALUED)

Still, the bullish narrative around Vertex Pharmaceuticals could be knocked off course if key late stage trials stumble, or if regulators and payers push back on high cost therapies.

Find out about the key risks to this Vertex Pharmaceuticals narrative.

Next Steps

With the tone of this Vertex Pharmaceuticals story skewing optimistic, it makes sense to pressure test the data yourself and move quickly while sentiment is still forming. To see what has investors focused on the upside case, review the 3 key rewards.

Looking for more Vertex Pharmaceuticals investment ideas?

Do not stop with Vertex Pharmaceuticals. Broaden your watchlist using focused screeners that surface different kinds of opportunities before they are widely talked about.

• Target resilient upside by scanning a 31 resilient stocks with low risk scores that filters for companies with lower risk scores and steadier fundamentals.
• Hunt for potential mispricings through a 38 high quality undervalued stocks that highlights financially stronger businesses trading below their estimated worth.
• Spot potential quiet outperformers using a 19 high quality undiscovered gems that focuses on high quality companies still flying under most investors' radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com